Elevated Neutrophil to Lymphocyte Ratio Predicts Poor Prognosis in Advanced Colorectal Cancer Patients Receiving Oxaliplatin-Based ChemotherapyKaneko M. · Nozawa H. · Sasaki K. · Hongo K. · Hiyoshi M. · Tada N. · Murono K. · Nirei T. · Kawai K. · Sunami E. · Tsuno N.H. · Kitayama J.
Department of Surgical Oncology, Faculty of Medicine, University of Tokyo, Tokyo, Japan
Background: The aim of this study was to assess whether the neutrophil to lymphocyte ratio (NLR) and other laboratory markers may predict the prognosis of advanced colorectal cancer (CRC) patients receiving palliative chemotherapy. Methods: The study population included 50 patients with far advanced or recurrent unresectable CRC who received oxaliplatin-based combination chemotherapy as first-line treatment in our hospital between June 2005 and November 2010. Seven clinical variables and 7 laboratory indices before chemotherapy were evaluated retrospectively as the possible prognostic factors of overall and progression-free survival. Results: During the study period, 27 patients (54%) died of CRC. Elevated NLR (≥4.0) was observed in 15 patients (30%). By univariate analysis, elevated NLR, performance status and hypoalbuminemia were significantly associated with both poor overall and progression-free survivals. Multivariate analysis showed that elevated NLR (hazard ratio 4.39, 95% confidence interval 1.82–10.7; p = 0.0013) and thrombocytosis (hazard ratio 5.02, 95% confidence interval 1.69–13.4; p = 0.0066) were independently associated with overall survival. Conclusion: Elevated NLR is a powerful predictor of poor response to oxaliplatin-based chemotherapy in patients with unresectable CRC. The ratio is a simply accessible and inexpensive but useful biomarker in CRC patients receiving chemotherapy.
© 2012 S. Karger AG, Basel
Received: November 14, 2011
Accepted after revision: February 7, 2012
Published online: April 26, 2012
Number of Print Pages : 8
Number of Figures : 3, Number of Tables : 5, Number of References : 42
Oncology (International Journal for Cancer Research and Treatment)
Vol. 82, No. 5, Year 2012 (Cover Date: May 2012)
Journal Editor: Markman M. (Philadelphia, Pa.)
ISSN: 0030-2414 (Print), eISSN: 1423-0232 (Online)
For additional information: http://www.karger.com/OCL